Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- John Sfakianos
- Target Recruit Count
- 60
- Registration Number
- NCT06503614
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Zhiyong Huang
- Target Recruit Count
- 50
- Registration Number
- NCT06470256
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 620
- Registration Number
- NCT06467357
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 66
- Registration Number
- NCT06464068
- Locations
- 🇮🇹
AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Target Recruit Count
- 42
- Registration Number
- NCT06440993
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇩🇪Universitätsklinikum Düsseldorf, Düsseldorf, Germany
🇩🇪Universitätsklinikum Köln, Köln, Germany
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 40
- Registration Number
- NCT06441747
- Locations
- 🇦🇺
Royal Brisbane Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
🇦🇺St John of God Hospital, Subiaco, Perth, Western Australia, Australia
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 29
- Registration Number
- NCT06419179
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Francesco De Cobelli
- Target Recruit Count
- 33
- Registration Number
- NCT06375915
- Locations
- 🇮🇹
Department of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT06371482
- Locations
- 🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT06333678
- Locations
- 🇺🇸
Lehigh Valley Health Network (Dara Collection Only), Allentown, Pennsylvania, United States
🇺🇸University of Miami (Data Collection Only), Miami, Florida, United States
🇺🇸University of Michigan (Data Collection Only), Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.